BR112022005193A2 - Composto de piridona fundido, método de preparação do mesmo e uso do mesmo - Google Patents

Composto de piridona fundido, método de preparação do mesmo e uso do mesmo

Info

Publication number
BR112022005193A2
BR112022005193A2 BR112022005193A BR112022005193A BR112022005193A2 BR 112022005193 A2 BR112022005193 A2 BR 112022005193A2 BR 112022005193 A BR112022005193 A BR 112022005193A BR 112022005193 A BR112022005193 A BR 112022005193A BR 112022005193 A2 BR112022005193 A2 BR 112022005193A2
Authority
BR
Brazil
Prior art keywords
preparing
molted
compound
pyridone compound
pyridone
Prior art date
Application number
BR112022005193A
Other languages
English (en)
Inventor
Guo Shuchun
Fan Jun
Liu Yang
Bao Fang
Peng Jianbiao
Guo Haibing
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of BR112022005193A2 publication Critical patent/BR112022005193A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPOSTO DE PIRIDONA FUNDIDO, MÉTODO DE PREPARAÇÃO DO MESMO E USO DO MESMO. São divulgados na presente invenção um composto de piridona fundido e um método de preparação para o mesmo e uso do mesmo. Especificamente, a presente invenção divulga um composto de fórmula (I-B), um isômero óptico do mesmo e um sal farmaceuticamente aceitável do mesmo, e o uso do composto como um inibidor de KRAS.
BR112022005193A 2019-09-20 2020-09-21 Composto de piridona fundido, método de preparação do mesmo e uso do mesmo BR112022005193A2 (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
CN201910892032 2019-09-20
CN201911129688 2019-11-18
CN201911157939 2019-11-22
CN202010054188 2020-01-17
CN202010102546 2020-02-19
CN202010230303 2020-03-27
CN202010306926 2020-04-17
CN202010367694 2020-04-30
CN202010967317 2020-09-15
PCT/CN2020/116510 WO2021052499A1 (zh) 2019-09-20 2020-09-21 稠合吡啶酮类化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
BR112022005193A2 true BR112022005193A2 (pt) 2022-08-16

Family

ID=74883935

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005193A BR112022005193A2 (pt) 2019-09-20 2020-09-21 Composto de piridona fundido, método de preparação do mesmo e uso do mesmo

Country Status (14)

Country Link
US (1) US20220389029A1 (pt)
EP (1) EP4043464A4 (pt)
JP (1) JP2022549171A (pt)
KR (1) KR20220086573A (pt)
CN (2) CN114728968A (pt)
AU (1) AU2020350745A1 (pt)
BR (1) BR112022005193A2 (pt)
CA (1) CA3155066A1 (pt)
CL (1) CL2022000666A1 (pt)
CO (1) CO2022004686A2 (pt)
IL (1) IL291467A (pt)
MX (1) MX2022003401A (pt)
TW (1) TWI761961B (pt)
WO (1) WO2021052499A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
MX2022005053A (es) 2019-10-28 2022-05-18 Merck Sharp & Dohme Llc Inhibidores de peque?as moleculas de mutante g12c de kras.
KR20220106765A (ko) * 2019-10-30 2022-07-29 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 치환된 헤테로환형 융합된 환형 화합물, 이의 제조 방법 및 이의 약학적 용도
MX2022007515A (es) 2019-12-20 2022-09-19 Mirati Therapeutics Inc Inhibidores de sos1.
US20230357272A1 (en) * 2020-04-03 2023-11-09 Medshine Discovery Inc. Octahydropyrazinodiazanaphthyridine dione compounds
CN116406363A (zh) * 2020-08-21 2023-07-07 浙江海正药业股份有限公司 四环类衍生物、其制备方法及其医药上的用途
WO2022143995A1 (zh) * 2020-12-31 2022-07-07 正大天晴药业集团股份有限公司 四环类化合物及其医药用途
CN116964056A (zh) * 2021-03-25 2023-10-27 上海济煜医药科技有限公司 稠合吡啶酮类化合物盐型、晶型及其应用
CN116848111A (zh) * 2021-03-26 2023-10-03 浙江海正药业股份有限公司 一种kras抑制剂关键中间体及其制备方法
CN115124533A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 四环类衍生物、其制备方法和其医药上的用途
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022223037A1 (zh) * 2021-04-22 2022-10-27 劲方医药科技(上海)有限公司 Kras抑制剂的盐或多晶型物
AU2022314009A1 (en) * 2021-07-23 2024-01-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
CN117222654A (zh) * 2021-09-06 2023-12-12 苏州赞荣医药科技有限公司 Kras g12c抑制剂和其用途
WO2023116895A1 (zh) * 2021-12-24 2023-06-29 劲方医药科技(上海)有限公司 Kras抑制剂的多晶型物及其制备方法和用途
CN116327956A (zh) * 2022-04-01 2023-06-27 劲方医药科技(上海)有限公司 药物组合物、其用途及癌症的治疗方法
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3055290B1 (en) * 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
BR112017021869A2 (pt) * 2015-04-10 2018-12-11 Araxes Pharma Llc compostos quinazolina substituídos e métodos de uso dos mesmos
EP3283462B1 (en) * 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US9988357B2 (en) * 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2018142365A1 (en) * 2017-02-03 2018-08-09 The University Of North Carolina At Chapel Hill Inhibitors of microbial beta-glucuronidase enzymes and uses thereof
CN110603258A (zh) * 2017-05-11 2019-12-20 阿斯利康(瑞典)有限公司 抑制g12c突变型ras蛋白的杂芳基化合物
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2019110751A1 (en) * 2017-12-08 2019-06-13 Astrazeneca Ab Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents
US11453667B2 (en) * 2018-01-19 2022-09-27 Medshine Discovery Inc. Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor
MX2020010836A (es) * 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
WO2020156285A1 (zh) * 2019-01-29 2020-08-06 博瑞生物医药（苏州）股份有限公司 一种苯并吡啶酮杂环化合物及其用途
WO2020239123A1 (zh) * 2019-05-31 2020-12-03 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
CN112300194B (zh) * 2019-07-30 2022-01-14 上海凌达生物医药有限公司 一类稠环吡啶酮类化合物、制备方法和用途
KR20220106765A (ko) * 2019-10-30 2022-07-29 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 치환된 헤테로환형 융합된 환형 화합물, 이의 제조 방법 및 이의 약학적 용도

Also Published As

Publication number Publication date
EP4043464A1 (en) 2022-08-17
WO2021052499A1 (zh) 2021-03-25
AU2020350745A1 (en) 2022-04-07
CA3155066A1 (en) 2021-03-25
EP4043464A4 (en) 2023-10-04
CL2022000666A1 (es) 2022-10-14
CN116947885A (zh) 2023-10-27
US20220389029A1 (en) 2022-12-08
IL291467A (en) 2022-05-01
KR20220086573A (ko) 2022-06-23
CN114728968A (zh) 2022-07-08
CO2022004686A2 (es) 2022-07-08
TW202126654A (zh) 2021-07-16
MX2022003401A (es) 2022-07-13
TWI761961B (zh) 2022-04-21
JP2022549171A (ja) 2022-11-24

Similar Documents

Publication Publication Date Title
BR112022005193A2 (pt) Composto de piridona fundido, método de preparação do mesmo e uso do mesmo
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
BR112022009557A2 (pt) Inibidores de kras g12c
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CL2017002090A1 (es) Inhibidores selectivos de bace1
CL2017002908A1 (es) Amidas heterocíclicas como inhibidores de quinasa.
CL2017002883A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CR20190124A (es) Inhibidores de ssao de aminopirimidina
CU20190086A7 (es) Compuestos de heteroarilo bicíclicos 6-6 fusionados útiles como inhibidores de lats
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
DK3880676T3 (da) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-on-derivater som hpk1-inhibitorer til behandling af cancer
WO2014105958A3 (en) Fused pyrimidine compounds and use thereof
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
CL2018001067A1 (es) Compuesto piranodipiridínico.
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
WO2018039077A8 (en) Therapeutic compounds
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa